4.6 Article

In-Silico Trials for Treatment of Acute Ischemic Stroke

Journal

FRONTIERS IN NEUROLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2020.558125

Keywords

INSIST; in-silicoclinical trials; acute ischemic stroke; in-silicomodeling; virtual patients; virtual populations; validation; simulation

Funding

  1. European Union's Horizon 2020 research and innovation program [777072]
  2. H2020 Societal Challenges Programme [777072] Funding Source: H2020 Societal Challenges Programme

Ask authors/readers for more resources

Despite improved treatment, a large portion of patients with acute ischemic stroke due to a large vessel occlusion have poor functional outcome. Further research exploring novel treatments and better patient selection has therefore been initiated. The feasibility of new treatments and optimized patient selection are commonly tested in extensive and expensive randomized clinical trials.in-silicotrials, computer-based simulation of randomized clinical trials, have been proposed to aid clinical trials. In this white paper, we present our vision and approach to set upin-silicotrials focusing on treatment and selection of patients with an acute ischemic stroke. The INSIST project (IN-Silicotrials for treatment of acute Ischemic STroke,) is a collaboration of multiple experts in computational science, cardiovascular biology, biophysics, biomedical engineering, epidemiology, radiology, and neurology. INSIST will generate virtual populations of acute ischemic stroke patients based on anonymized data from the recent stroke trials and registry, and build on the existing and emergingin-silicomodels for acute ischemic stroke, its treatment (thrombolysis and thrombectomy) and the resulting perfusion changes. These models will be used to design a platform forin-silicotrials that will be validated with existing data and be used to provide a proof of concept of the potential efficacy of this emerging technology. The platform will be used for preliminary evaluation of the potential suitability and safety of medication, new thrombectomy device configurations and methods to select patient subpopulations for better treatment outcome. This could allow generating, exploring and refining relavant hypotheses on potential causal pathways (which may follow from the evidence obtained from clinical trials) and improving clinical trial design. Importantly, the findings of thein-silicotrials will require validation under the controlled settings of randomized clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available